Drugs / Balovaptan
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT03912350 | Jun → Sep 2022 | autism spectrum disorder | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 1 | NCT04049578 | Dec 2019 → Apr 2020 | autism spectrum disorder | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT04156646 | Nov → Dec 2019 | autism spectrum disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03808298 | Feb → Jun 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03764449 | Jan → Mar 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03586726 | Jul → Nov 2018 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03579719 | Jul → Nov 2018 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02205073 | Jul 2014 → Oct 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02179866 | Jun → Jul 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01967979 | Oct → Dec 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01708616 | Nov 2012 → Feb 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01418963 | Jul 2011 → Jul 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT05401565 | Aug 2022 → Oct 2023 | post-traumatic stress disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT05399550 | Jun → Nov 2022 | ischemic stroke | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 2 | NCT02901431 | Nov 2016 → Apr 2020 | autism spectrum disorder | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 2 | NCT01793441 | Sep 2013 → Sep 2016 | autism spectrum disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03504917 | Aug 2018 → Mar 2020 | autism spectrum disorder | Hoffmann-La Roche | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | balovaptan | “BACKGROUND: Balovaptan is a potent, selective vasopressin 1a receptor antagonist.” PMID 34176392 ↗ Jul 202111“Balovaptan (RO5285119) 10 mg/d equivalent” NCT02901431 ↗ |
| Known as | RG7314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01793441 ↗ |
| Known as | RO5285119 | “Balovaptan (RO5285119) 10 mg/d equivalent” NCT02901431 ↗ |
| Action | Inhibit | “Balovaptan is a potent, selective vasopressin 1a receptor antagonist.” PMID 34176392 ↗ Jul 20211“Vasopressin V1a receptor antagonist” CHEMBL4297183 ↗ |
| Modality | Small molecule | — CHEMBL4297183 ↗ |
| Route | Oral | “Following Oral Administration” NCT01418963 ↗ |
| Target | AVPR1A | “Vasopressin V1a receptor antagonist” CHEMBL4297183 ↗ |